Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NODAGA-E[c(RGDyK)]2 Angiogenesis PET in Ischemic Heart Disease
2024-518640-20-00Phase 2Authorised
- Sponsor
- Rigshospitalet
- Start
- Jan 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 68Ga-NODAGA-E(c[RGDyK])2 in Chronic Coronary Syndrome (CCS), sponsored by Rigshospitalet. Planned start Jan 2025; status: authorised.
02
Drugs
68Ga-NODAGA-E(c[RGDyK])2
03
Conditions
Chronic Coronary Syndrome (CCS)
Beyond the preview
Go deeper on 2024-518640-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518640-20-00.